Table 1.

Summary of Studies Investigating Cardiovascular Outcomes After Acute Coronary Event or Coronary Revascularization

Study, Publication Year	Population	% ACS	Baseline	Follow‐Up, mo	% ART (PLHIV)	Age, y	Recurrent Event^*	No. of PLHIV	No. of HIV(−)	Matching Variables for HIV(−) Controls
Current study ⁸	ACS	100	2003–2006	36	93	49	Cardiovascular death, MI, ACS, TLR, TVR, stroke, MACCE, HF hospitalization	103	195	Age, sex, ACS type, center, event date
Badr, 2015 ¹⁹	PCI	59	2003–2011	24	NR	58	Cardiac death, MI, TLR, TVR, MACE	112	112	Age, sex, diabetes mellitus, PCI
Carballo, 2015 ⁷	MI	100	2005–2011	12	80	51	Cardiovascular death, MI	133	4934	MI, study period
Lorgis, 2013 ¹⁰	MI	100	2005–2009	12	NR	50	MI, revascularization, HF hospitalization	435	945	Age, sex
Ren, 2009 ²⁰	PCI	81	2000–2007	37	81	53	Cardiovascular death, MI, TVR, TLR, CABG, MACE	97	97	Age, sex, PCI, PCI period
Boccara, 2006 ²¹	PCI	98	2001–2003	20	96	43	MI, restenosis, MACE	50	50	Age, sex, event period, PCI
Hsue, 2004 ¹²	ACS	100	1993–2003	NR	53	50	Restenosis	68	68	Event date
Matetzky, 2003 ²²	MI	100	1998–2000	15	92	47	Cardiac death, MI, ACS, revascularization, HF hospitalization	24	48	Age, sex, AMI type, event date

ACS indicates acute coronary syndrome; ART, antiretroviral therapy; CABG, coronary artery bypass graft; HF, heart failure; MACCE, major adverse cardiac and cerebrovascular event; MACE, major adverse cardiac event; MI, myocardial infarction; NR, not reported; PCI, percutaneous coronary intervention; PLHIV, people living with HIV; TLR, target lesion revascularization; and TVR, target vessel revascularization.

MACE includes ACS, revascularization, and cardiac death; and revascularization indicates PCI or CABG.